Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smarter dosing for kids with superbug infections?

NCT ID NCT02694458

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an early, computer-guided dosing strategy for vancomycin helps children with MRSA infections reach the right drug levels faster than the usual approach. 100 children aged 1 month to 16 years took part. The goal was to improve treatment effectiveness while avoiding toxic side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vancomycin
What this could lead to
If successful, this approach could help children with MRSA get the right dose of vancomycin sooner, improving treatment and reducing side effects.
What could go wrong
This is a small, single-hospital study testing a dosing method, not a new drug. The strategy may not work for all children or in other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Feb 2016

Finished

Feb 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 month to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 1 months to 16 years * Children for whom a vancomycin treatment is started in the hospital Necker-Enfants Malades in Paris, France * No objection of parents and of the child himself if he is able to express it. Exclusion Criteria: * Patients undergoing hemodialysis * Patients undergoing peritoneal dialysis * Newborns less than 1 months old * Adolescents more than 16 years old and adults

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methicillin-resistant staphylococcal infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections methicillin-resistant staphylococcus aureus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methicillin-resistant staphylococcal infections

Contacts and locations

Locations

  • Hôpital Necker-Enfants Malades

    Paris, Paris, 75015, France